{"id":"W2599456777","doi":"10.1200/jco.2006.24.18_suppl.14513","title":"Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Clinical endpoint; Capecitabine; Internal medicine; Prostate cancer; Urology; Refractory (planetary science); Gastroenterology; Phases of clinical research; Chemotherapy; Randomized controlled trial; Surgery; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001446829,0.002373949,0.002913221,0.0004943042,0.0004582437,0.001223638,0.0009644584,0.001332652,0.008345259],"category_scores_gemma":[0.00104242,0.0008958183,0.001407381,0.0006229322,0.001439135,0.0009249221,0.0004980782,0.003147707,0.001661558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009423452,"about_ca_system_score_gemma":0.001746576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00137425,"about_ca_topic_score_gemma":0.003327755,"domain_scores_codex":[0.9995432,0.0002331212,0.00001943547,0.00009246501,0.00002680328,0.00008496289],"domain_scores_gemma":[0.9992787,0.0001106841,0.0001143054,0.00005511545,0.00003184318,0.0004093195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.965724,0.01148116,0.0008494115,0.0002955848,0.0004072817,0.00005863016,0.0000704246,0.0004772915,0.003724138,0.0001675478,0.001312,0.01543257],"study_design_scores_gemma":[0.924787,0.07238557,0.001156423,0.0000140739,0.000163336,0.00004502648,0.0000165869,0.0003402196,0.000296185,0.000117674,0.00066696,0.00001081038],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843612,0.002003062,0.0009358446,0.0006229914,0.0004487384,0.00698355,0.001456361,0.0002030057,0.002985259],"genre_scores_gemma":[0.9818562,0.001720517,0.001980837,0.001353737,0.0003361448,0.006197087,0.002099683,0.00004212259,0.004413694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008345259,"threshold_uncertainty_score":0.02791762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07944983119989771,"score_gpt":0.4741449583049285,"score_spread":0.3946951271050307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}